Opdivo Now Approved for Classical Hodgkin Lymphoma Treatment
May 20th 2016The FDA has approved Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma who have relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin (Adcetris) treatment.
Read More